Private Trust Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Private Trust Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-72	Closed	-$2.62K	–	2648
2025 Q2	$2.62K	Hold	72	–	–	﹤0.01%	2211
2025 Q1	$2.61K	Hold	72	–	–	﹤0.01%	2210
2024 Q4	$3.03K	Hold	72	–	–	﹤0.01%	2113
2024 Q3	$4K	Buy	72 +24	+50%	+$1.22K	﹤0.01%	2018
2024 Q2	$1.97K	Sell	48 -6	-11%	-$256	﹤0.01%	2152
2024 Q1	$2.52K	Hold	54	–	–	﹤0.01%	2084
2023 Q4	$2.58K	Hold	54	–	–	﹤0.01%	2086
2023 Q3	$1.93K	Hold	54	–	–	﹤0.01%	2125
2023 Q2	$2.49K	Hold	54	–	–	﹤0.01%	2070
2023 Q1	$2.17K	Sell	54 -8	-13%	-$343	﹤0.01%	2067
2022 Q4	$3K	Sell	62 -9	-13%	-$354	﹤0.01%	1956
2022 Q3	$3K	Buy	71 +28	+65%	+$1.44K	﹤0.01%	1823
2022 Q2	$3K	Buy	+43	New	+$2.65K	﹤0.01%	1896

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Private Trust Company's RARE Position: Q3 2025 in Review

Private Trust Company sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 72 shares — an estimated $2.62K sold.

Private Trust Company first reported a position in RARE in Q2 2022 and held it in 13 quarters. The position peaked at $4K in Q3 2024. 302 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

Private Trust Company reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Private Trust Company sold 72 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $2.62K.
Private Trust Company first reported a position in Ultragenyx Pharmaceutical in Q2 2022 and held it in 13 quarters.
Private Trust Company's Ultragenyx Pharmaceutical position peaked at $4K in Q3 2024.
302 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Private Trust Company's 13F filing for Q3 2025, filed 15 Oct 2025.